Andrew Allen

last updated 6/30/2018

Andrew R. Allen

President and Chief Executive Officer at Gritstone Oncology

5858 Horton St, Suite 210, Emeryville, California, United States

General Information


Cambridge Healthtech Institute

Executive Vice President of Clinical and Pre-Clinical Development and Chief Medical Officer - Clovis Oncology, Inc.

Chief Medical Officer and Executive Vice President - Pharmion Corporation

Head of the Oncology Therapeutic Unit - Chiron Corp.

Main Board Director - Nuffield Hospitals


Bachelors - Life Sciences , Nursing Licensure or Pharmacy , 

Ph. D.Imperial College of Science , Technology and Medicine

Ph. D. - Immunology , Imperial College , London

Ph. D. - immunology , Imperial College London

medical degreeOxford University


Board Member - Epizyme, Inc.

Board Member - Revitope Oncology Inc

Board Member - ProNAi Therapeutics , Inc.

Board Member - Nodality Inc

Scientific Advisory Board - PBS-Bio Inc

Board Member - Cell Design Labs , Inc.

Member - Royal College of Physicians

Founder - Cardinal Healthcare

Recent News  

Board of Directors - Epizyme

Andrew R. Allen, M.D., Ph.D.
Andrew R. Allen, M.D., Ph.D Andrew R. Allen, MA BM BCh MRCP PhD, has served as a director since June 2014. Dr. Allen is co-founder and CEO of Gritstone Oncology, a venture-backed next-generation personalized cancer immunotherapy company that formed in mid-2015. Previously he was co-founder and CMO of Clovis Oncology, Inc. Prior to Clovis, he served in the CMO role at Pharmion Corporation (acquired by Celgene in 2008), as Vice President of BioPharma Development and Head of the Oncology Therapeutic Unit for Chiron Corporation (acquired by Novartis in 2005), and as global project head in Abbott Laboratories' oncology franchise. Previously, Dr. Allen was with the management consulting firm McKinsey & Company, focusing on oncology strategy. He also serves on the board of directors of Revitope Oncology, Inc., and Cell Design Labs, both privately-held biotechnology companies. Dr. Allen qualified in medicine at Oxford University, earned his Ph.D. from the Imperial College of Science, Technology and Medicine in London, and obtained post-graduate internal medicine qualification as a Member of Royal College of Physicians.

Read More
Speaker Biographies

Andrew Allen, MD, PhD, President & CEO, Gritstone Oncology, Inc.
Dr. Andrew Allen is a co-founder of Gritstone Oncology and serves as president, chief executive officer and a member of the board of directors. He was a co-founder of Clovis Oncology where he served as executive vice president of clinical and preclinical development and chief medical officer. Prior to that, he was chief medical officer at Pharmion Corporation, which was sold to Celgene Corporation for $2.9 billion following the development of Vidaza™ for the treatment of myelodysplastic syndromes and Thalomid™ for the front-line treatment of multiple myeloma. Previously, Dr. Allen served in clinical development leadership roles at Chiron Corporation and Abbott Laboratories, and worked at McKinsey & Company, where he advised life science companies on strategic issues. He currently serves on the board of directors of Epizyme and Cell Design Labs. Dr. Allen received a medical degree from Oxford University and a Ph.D. in immunology from Imperial College London.

Read More
Contact Us | Biotechnology & Pharmaceutical Recruiting

- Andrew Allen, MD, PhD - President and CMO, Gritstone Oncology

Read More

Browse ZoomInfo’s Directories